Laws and Labels: A Regulatory View of Biosimilars

Friday, October 30, 2015
Presented by: 
Erika Lietzan

Now that the first biosimilar product has been approved by FDA, healthcare professionals need to get up to speed on the evolving rules and policies that will separate biosimilars from interchangeable biologics and branded products. Join healthcare legal expert Erika Lietzan for a webinar examining the latest from the FDA on labeling biosimilars, the scientific and legal differences between biosimilars and other products, and the potential impact on prescribing and dispensing practices.

You may also like:

Blog Post

It is one of the most talked about issues in healthcare. The population of the United States (and the world!) is aging. In 2010, 40 million Americans were age 65 and older, and that number is projected to swell to 88 million by 20...

View Blog Post
Blog Post

Two independent studies show that there is very little bleeding risk in patients undergoing dental surgery who are medicated with the new anticoagulants and that dose omission before or after dental surgery is not necessary. “Ne...

View Blog Post
Blog Post

Many pharmacies are exploring the issue of accreditation. They wonder: What will it take? Will it be worth the time, effort, and investment? These are valid questions, and we’ll attempt to answer them here. Wh...

View Blog Post

RxPerts Academy

Stay in the Know

Sign up to start receiving notifications via email of our upcoming webinars!

Sign Up